600812 华北制药
已收盘 09-18 15:00:00
资讯
新帖
简况
华北制药：截至2026年6月30日，公司股东总数为88,579户
证券之星 · 09-18 18:15
华北制药：截至2026年6月30日，公司股东总数为88,579户
华北制药：公司及下属单位原料药苄星青霉素及制剂药注射用苄星青霉素
证券之星 · 09-18 18:06
华北制药：公司及下属单位原料药苄星青霉素及制剂药注射用苄星青霉素
华北制药：青霉素类产品共计30多种
证券之星 · 09-18 18:06
华北制药：青霉素类产品共计30多种
华北制药：高精度、大通量、高协同的模块化微反应器创制及产业创新性应用
证券之星 · 09-07
华北制药：高精度、大通量、高协同的模块化微反应器创制及产业创新性应用
华北制药：持续深化改革推动高质量发展
证券之星 · 09-07
华北制药：持续深化改革推动高质量发展
华北制药：公司积极推进相关产品研发事宜
证券之星 · 09-07
华北制药：公司积极推进相关产品研发事宜
华北制药：2026年上半年有息负债规模较年初有所降低
证券之星 · 09-07
华北制药：2026年上半年有息负债规模较年初有所降低
每周股票复盘：华北制药（600812）为子公司担保1.8亿元
证券之星 · 09-06
每周股票复盘：华北制药（600812）为子公司担保1.8亿元
华北制药（600812）披露为下属子公司提供担保公告，9月2日股价下跌1.64%
证券之星 · 09-02
华北制药（600812）披露为下属子公司提供担保公告，9月2日股价下跌1.64%
股市必读：华北制药新发布《关于下属公司获得《药品补充申请批准通知书》的公告》
证券之星 · 08-31
股市必读：华北制药新发布《关于下属公司获得《药品补充申请批准通知书》的公告》
每周股票复盘：华北制药（600812）注射用赖氨匹林通过一致性评价
证券之星 · 08-30
每周股票复盘：华北制药（600812）注射用赖氨匹林通过一致性评价
华北制药最新公告：子公司注射用赖氨匹林通过一致性评价并新增规格
证券之星 · 08-27
华北制药最新公告：子公司注射用赖氨匹林通过一致性评价并新增规格
每周股票复盘：华北制药（600812）Q2净利降57.01%
证券之星 · 08-23
每周股票复盘：华北制药（600812）Q2净利降57.01%
图解华北制药中报：第二季度单季净利润同比下降57.01%
证券之星 · 08-22
图解华北制药中报：第二季度单季净利润同比下降57.01%
华北制药最新公告：子公司获六价重组诺如病毒疫苗临床试验批准
证券之星 · 08-21
华北制药最新公告：子公司获六价重组诺如病毒疫苗临床试验批准
华北制药（600812）披露高级管理人员辞职公告，8月5日股价下跌2.26%
证券之星 · 08-05
华北制药（600812）披露高级管理人员辞职公告，8月5日股价下跌2.26%
华北制药：副总经理常志山因工作原因辞职
财中社 · 08-05
华北制药：副总经理常志山因工作原因辞职
股市必读：华北制药新发布《关于公司及下属子公司药品参与全国药品集中采购拟中选的公告》
证券之星 · 08-04
股市必读：华北制药新发布《关于公司及下属子公司药品参与全国药品集中采购拟中选的公告》
华北制药(600812.SH)：环孢素软胶囊等药品拟中选全国药品集中采购
智通财经 · 08-03
华北制药(600812.SH)：环孢素软胶囊等药品拟中选全国药品集中采购
冀中能源集团华北制药两项成果获评全国质量创新专业Ⅱ级奖项
市场资讯 · 07-31
冀中能源集团华北制药两项成果获评全国质量创新专业Ⅱ级奖项
加载更多
公司概况
公司名称：
华北制药股份有限公司
所属行业：
医药制造业
上市日期：
1994-01-14
主营业务：
华北制药股份有限公司的主营业务是医药产品的研发、生产和销售。公司的主要产品是化学药、生物药、维生素及健康消费品、农兽药。
发行价格：
4.00
{"stockData":{"symbol":"600812","market":"SH","secType":"STK","nameCN":"华北制药","latestPrice":4.62,"timestamp":1789714802000,"preClose":4.53,"halted":0,"volume":29919595,"delay":0,"changeRate":0.0199,"floatShares":1716000000,"shares":1716000000,"eps":0.072,"marketStatus":"已收盘","change":0.09,"latestTime":"09-18 15:00:00","open":4.52,"high":4.84,"low":4.52,"amount":139000000,"amplitude":0.0706,"askPrice":4.63,"askSize":248,"bidPrice":4.62,"bidSize":873,"shortable":0,"etf":0,"ttmEps":0.072,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789954200000},"marketStatusCode":5,"adr":0,"adjPreClose":4.53,"symbolType":"stock","openAndCloseTimeList":[[1789695000000,1789702200000],[1789707600000,1789714800000]],"highLimit":4.98,"lowLimit":4.08,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1715730370,"isCdr":false,"pbRate":1.44,"roa":"--","peRate":64.166667,"roe":"1.15%","epsLYR":0.107,"committee":-0.061109,"marketValue":7927000000,"turnoverRate":0.0174,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-09-21。","floatMarketCap":7927000000},"requestUrl":"/m/hq/s/600812","defaultTab":"news","newsList":[{"id":"2668947846","title":"华北制药：截至2026年6月30日，公司股东总数为88,579户","url":"https://stock-news.laohu8.com/highlight/detail?id=2668947846","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668947846?lang=zh_cn&edition=full","pubTime":"2026-09-18 18:15","pubTimestamp":1789726511,"startTime":"0","endTime":"0","summary":"证券之星消息，华北制药(600812)09月18日在投资者关系平台上答复投资者关心的问题。投资者提问：公司股价为什么上蹿下跳，能否查询股东户数，是不是又把散户套住了华北制药回复：尊敬的投资者，您好。公司按要求在定期报告中披露截至报告期末的股东人数。截至2026年6月30日，公司股东总数为88,579户。具体内容请详见《2026年半年度报告》第六节股份变动及股东情况相关内容。感谢您的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091800028750.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","600812","BK0191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668194275","title":"华北制药：公司及下属单位原料药苄星青霉素及制剂药注射用苄星青霉素","url":"https://stock-news.laohu8.com/highlight/detail?id=2668194275","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668194275?lang=zh_cn&edition=full","pubTime":"2026-09-18 18:06","pubTimestamp":1789725985,"startTime":"0","endTime":"0","summary":"证券之星消息，华北制药(600812)09月18日在投资者关系平台上答复投资者关心的问题。投资者提问：公司有抗感染治疗梅毒的药品吗？华北制药回复：尊敬的投资者，您好。公司及下属单位原料药苄星青霉素及制剂药注射用苄星青霉素，主要用于预防风湿热复发，也可用于控制链球菌感染的流行。治疗用药还请谨遵医嘱。上述产品收入占公司总收入的比重较小。敬请投资者审慎决策，注意投资风险。具体情况请参见《2025年年度报告》及相关公告，感谢您的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091800028506.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600812","BK0028","BK0191","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668759942","title":"华北制药：青霉素类产品共计30多种","url":"https://stock-news.laohu8.com/highlight/detail?id=2668759942","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668759942?lang=zh_cn&edition=full","pubTime":"2026-09-18 18:06","pubTimestamp":1789725969,"startTime":"0","endTime":"0","summary":"证券之星消息，华北制药(600812)09月18日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好！贵公司青梅素是否提供海外？另外，2026年青梅素厂存多少谢谢华北制药回复：尊敬的投资者，您好。目前公司青霉素类产品共计30多种，其中原料药阿莫西林、普鲁卡因青霉素，以及制剂药阿莫西林胶囊等产品出口海外市场。公司2025年全年实现出口收入19.53亿元。具体情况请参见《2025年年度报告》及相关公告，感谢您的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091800028493.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0191","600812","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665147083","title":"华北制药：高精度、大通量、高协同的模块化微反应器创制及产业创新性应用","url":"https://stock-news.laohu8.com/highlight/detail?id=2665147083","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665147083?lang=zh_cn&edition=full","pubTime":"2026-09-07 18:00","pubTimestamp":1788775228,"startTime":"0","endTime":"0","summary":"证券之星消息，华北制药09月07日在投资者关系平台上答复投资者关心的问题。后续公司将继续围绕“五大板块”协同发展，以“提质增效”为中心，深化营销改革，坚持创新驱动，扩大出口规模，持续降本增效，加快重点项目建设，探索多形式对外合作，稳步提升盈利水平。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700024078.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","600812","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665314895","title":"华北制药：持续深化改革推动高质量发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2665314895","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665314895?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:48","pubTimestamp":1788774495,"startTime":"0","endTime":"0","summary":"证券之星消息，华北制药09月07日在投资者关系平台上答复投资者关心的问题。二级市场股价易受多重市场外部因素影响。公司将继续围绕“五大板块”协同发展，持续深化改革，推动营销变革，突出科技引领，夯实管理根基，奋力推动公司高质量发展。感谢您对公司的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700023233.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0191","BK0028","600812"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665314813","title":"华北制药：公司积极推进相关产品研发事宜","url":"https://stock-news.laohu8.com/highlight/detail?id=2665314813","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665314813?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:48","pubTimestamp":1788774494,"startTime":"0","endTime":"0","summary":"证券之星消息，华北制药(600812)09月07日在投资者关系平台上答复投资者关心的问题。投资者提问：阿尔兹海默症的药品开发进度能不能说明下？华北制药回复：尊敬的投资者，您好。公司积极推进相关产品研发事宜。由于药品的前期研发以及产品从研制、临床试验报批到投产的周期长、环节多，容易受到技术、审批、政策等诸多因素影响，敬请投资者注意投资风险。感谢您的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700023232.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","600812","BK0191","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665314844","title":"华北制药：2026年上半年有息负债规模较年初有所降低","url":"https://stock-news.laohu8.com/highlight/detail?id=2665314844","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665314844?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:48","pubTimestamp":1788774488,"startTime":"0","endTime":"0","summary":"证券之星消息，华北制药09月07日在投资者关系平台上答复投资者关心的问题。有计划通过增发补充流动资金吗华北制药回复：尊敬的投资者，您好。公司拓展融资渠道，优化融资结构，2025年上半年成功发行5亿元短期融资券，10月成功发行2025年第一期科技创新债券5亿元；2026年上半年公司有息负债规模较年初有所降低，强化资金管控，财务费用较同期下降1289万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700023224.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","BK0239","BK0028","600812"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665036663","title":"每周股票复盘：华北制药（600812）为子公司担保1.8亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2665036663","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665036663?lang=zh_cn&edition=full","pubTime":"2026-09-06 03:39","pubTimestamp":1788637150,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘，华北制药报收于4.69元，较上周的4.93元下跌4.87%。本周，华北制药8月31日盘中最高价报4.91元。华北制药当前最新总市值80.47亿元，在化学制药板块市值排名62/149，在两市A股市值排名2191/5214。截至公告日，公司及控股子公司对外担保总额为81,274万元，占最近一期经审计净资产的14.74%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090600001253.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600812","BK0028","BK0239","BK0191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664810518","title":"华北制药（600812）披露为下属子公司提供担保公告，9月2日股价下跌1.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664810518","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664810518?lang=zh_cn&edition=full","pubTime":"2026-09-02 22:44","pubTimestamp":1788360255,"startTime":"0","endTime":"0","summary":"截至2026年9月2日收盘，华北制药报收于4.79元，较前一交易日下跌1.64%，最新总市值为82.18亿元。近日，华北制药股份有限公司发布《关于为下属子公司提供担保的公告》。本次担保在公司2025年年度股东会审议通过的担保额度内，无需另行审议。截至公告日，公司及控股子公司对外担保总额为81,274万元，占最近一期经审计净资产的14.74%。存在逾期担保金额9,000万元，系对石家庄焦化集团有限责任公司的担保，目前该债务已被转让，执行程序中止。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200043218.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","BK0239","BK0028","600812"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663304051","title":"股市必读：华北制药新发布《关于下属公司获得《药品补充申请批准通知书》的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2663304051","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663304051?lang=zh_cn&edition=full","pubTime":"2026-08-31 06:36","pubTimestamp":1788129372,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，华北制药报收于4.93元，下跌0.4%，换手率0.78%，成交量13.31万手，成交额6533.15万元。当日关注点交易信息汇总：8月28日主力资金净流出735.11万元，占总成交额11.25%。公司公告汇总：全资子公司深圳华药南方制药获注射用赖氨匹林两个规格《药品补充申请批准通知书》，0.9g规格通过仿制药一致性评价，1.8g规格获批并核发药品批准文号。该产品累计研发投入311.42万元，后续可安排生产和上市销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100001646.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600812","BK0191","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663048896","title":"每周股票复盘：华北制药（600812）注射用赖氨匹林通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2663048896","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663048896?lang=zh_cn&edition=full","pubTime":"2026-08-30 04:56","pubTimestamp":1788036969,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，华北制药报收于4.93元，较上周的4.91元上涨0.41%。本周，华北制药8月27日盘中最高价报4.96元。8月24日盘中最低价报4.56元。华北制药当前最新总市值84.59亿元，在化学制药板块市值排名61/149，在两市A股市值排名2093/5211。本周关注点来自公司公告汇总：注射用赖氨匹林0.9g规格通过仿制药质量和疗效一致性评价，1.8g规格获批并核发药品批准文号。该产品累计研发投入311.42万元，后续可安排生产和上市销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000001492.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","600812","BK0191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662707587","title":"华北制药最新公告：子公司注射用赖氨匹林通过一致性评价并新增规格","url":"https://stock-news.laohu8.com/highlight/detail?id=2662707587","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662707587?lang=zh_cn&edition=full","pubTime":"2026-08-27 17:49","pubTimestamp":1787824175,"startTime":"0","endTime":"0","summary":"华北制药(600812.SH)公告称，公司全资子公司深圳华药南方制药有限公司收到国家药监局核准签发的注射用赖氨匹林(0.9g、1.8g)《药品补充申请批准通知书》，该产品通过仿制药质量和疗效一致性评价，并新增1.8g规格。该药品用于不适用于口服给药的发热及轻、中度疼痛治疗。2025年该产品销售收入1173万元。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700041841.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600812","BK0239","BK0191","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661111282","title":"每周股票复盘：华北制药（600812）Q2净利降57.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661111282","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661111282?lang=zh_cn&edition=full","pubTime":"2026-08-23 02:04","pubTimestamp":1787421855,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，华北制药报收于4.91元，较上周的5.04元下跌2.58%。本周，华北制药8月18日盘中最高价报5.22元。股本股东变化股东户数变动截至2026年6月30日，华北制药股东户数为8.86万户，较3月31日减少3223户，减幅3.51%。业绩披露要点财务报告华北制药2026年中报显示，上半年主营收入42.2亿元，同比下降20.01%；归母净利润6384.59万元，同比下降48.3%；扣非净利润5857.59万元，同比下降51.16%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300000330.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600812","BK0028","BK0191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661041294","title":"图解华北制药中报：第二季度单季净利润同比下降57.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661041294","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661041294?lang=zh_cn&edition=full","pubTime":"2026-08-22 01:55","pubTimestamp":1787334938,"startTime":"0","endTime":"0","summary":"证券之星消息，华北制药2026年中报显示，上半年度公司主营收入42.2亿元，同比下降20.01%；归母净利润6384.59万元，同比下降48.3%；扣非净利润5857.59万元，同比下降51.16%；其中2026年第二季度，公司单季度主营收入20.66亿元，同比下降23.49%；单季度归母净利润2837.31万元，同比下降57.01%；单季度扣非净利润2631.17万元，同比下降59.35%；负债率67.49%，投资收益3163.22万元，财务费用1.64亿元，毛利率27.04%。财报数据概要请见下图:本文数据来源于华北制药2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082200002066.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600812"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661260210","title":"华北制药最新公告：子公司获六价重组诺如病毒疫苗临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2661260210","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661260210?lang=zh_cn&edition=full","pubTime":"2026-08-21 20:00","pubTimestamp":1787313643,"startTime":"0","endTime":"0","summary":"华北制药(600812.SH)公告称，公司下属控股子公司金坦公司收到国家药监局核准签发的六价重组诺如病毒疫苗(汉逊酵母)《药物临床试验批准通知书》，同意开展预防六种诺如病毒基因型感染引起的急性胃肠炎临床试验。截至2026年7月，该药品累计研发费用2453.75万元。目前全球尚无获批上市的诺如病毒疫苗，金坦公司已形成“四价+六价”梯次布局。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100040625.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159646","BK0028","600812","BK0191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657523938","title":"华北制药（600812）披露高级管理人员辞职公告，8月5日股价下跌2.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657523938","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657523938?lang=zh_cn&edition=full","pubTime":"2026-08-05 22:31","pubTimestamp":1785940273,"startTime":"0","endTime":"0","summary":"截至2026年8月5日收盘，华北制药报收于4.76元，较前一交易日下跌2.26%，最新总市值为81.67亿元。近日，华北制药股份有限公司披露《关于高级管理人员辞职的公告》。公告显示，公司董事会于2026年8月4日收到副总经理常志山先生递交的书面辞职报告。常志山先生因工作原因申请辞去公司副总经理职务，辞职后不再担任公司任何职务。其辞职报告自送达董事会之日起生效。公司董事会对常志山先生在职期间为公司发展作出的贡献表示感谢。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500043618.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","BK0239","BK0028","600812"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657467495","title":"华北制药：副总经理常志山因工作原因辞职","url":"https://stock-news.laohu8.com/highlight/detail?id=2657467495","media":"财中社","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657467495?lang=zh_cn&edition=full","pubTime":"2026-08-05 19:00","pubTimestamp":1785927600,"startTime":"0","endTime":"0","summary":"8月5日，华北制药（维权）（600812）发布公告，常志山因工作原因，申请辞去公司副总经理职务，之后不再担任公司任何职务。2026年一季度，华北制药实现收入21.53亿元，归母净利润3547万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/zqgd/2026-08-05/doc-inimhiei4582459.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0191","BK0028","BK0239","600812"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656057273","title":"股市必读：华北制药新发布《关于公司及下属子公司药品参与全国药品集中采购拟中选的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2656057273","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656057273?lang=zh_cn&edition=full","pubTime":"2026-08-04 02:04","pubTimestamp":1785780259,"startTime":"0","endTime":"0","summary":"截至2026年8月3日收盘，华北制药报收于4.86元，上涨0.83%，换手率0.69%，成交量11.76万手，成交额5707.35万元。公司公告汇总：华北制药及下属子公司8个药品拟中选第十二批全国药品集采，采购周期至2029年12月31日。拟中选结果公示期为2026年7月31日至8月5日。相关产品2025年度及2026年第一季度销售收入占公司营业收入比例较小，预计短期内对公司业绩影响有限。后续采购合同签订及销售执行存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400001544.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0191","600812","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656324077","title":"华北制药(600812.SH)：环孢素软胶囊等药品拟中选全国药品集中采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2656324077","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656324077?lang=zh_cn&edition=full","pubTime":"2026-08-03 16:52","pubTimestamp":1785747130,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华北制药 发布公告，近日，公司及下属子公司华北制药河北华民药业有限责任公司、深圳华药南方制药有限公司参加了国家组织药品联合采购办公室组织的第十二批全国药品集中采购的投标工作。本次公司及华民公司、南方公司参加的第十二批全国药品集中采购8个品种全部拟中选。本次集中采购是国家组织的第十二批药品集中带量采购，采购周期中，医疗机构将优先使用本次药品集中带量采购中选品种，并确保完成约定采购量。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475274.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600812","BK0239","BK0191","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655936293","title":"冀中能源集团华北制药两项成果获评全国质量创新专业Ⅱ级奖项","url":"https://stock-news.laohu8.com/highlight/detail?id=2655936293","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655936293?lang=zh_cn&edition=full","pubTime":"2026-07-31 21:32","pubTimestamp":1785504720,"startTime":"0","endTime":"0","summary":"近日，第七届全国质量创新与质量改进成果交流活动成功举办。冀中能源集团华北制药华民公司参与的《注射用头孢噻吩钠分装工艺控制技术研究与应用》和《头孢类原料药中基因毒性杂质M和DM检测方法的开发》两项成果获评全国质量创新专业Ⅱ级奖项。本次活动汇聚航天军工、高端制造、医药、汽车等多行业数百家企业，共计580余项成果同台竞技。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-07-31/doc-iniktkaz4353545.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["000937","BK0266","BK0028","BK0239","BK0188","BK0191","600812"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1789764280138,"stockEarnings":[{"period":"1week","weight":-0.0648},{"period":"1month","weight":-0.087},{"period":"3month","weight":0.0548},{"period":"6month","weight":-0.1424},{"period":"1year","weight":-0.2238},{"period":"ytd","weight":-0.1579}],"compareEarnings":[{"period":"1week","weight":0.0061},{"period":"1month","weight":0.0045},{"period":"3month","weight":-0.0437},{"period":"6month","weight":-0.0114},{"period":"1year","weight":0.0209},{"period":"ytd","weight":-0.0144}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"华北制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"88579人(较上一季度减少3.51%)","perCapita":"19369股","listingDate":"1994-01-14","address":"河北省石家庄市长安区和平东路388号","registeredCapital":"171573万元","survey":" 华北制药股份有限公司的主营业务是医药产品的研发、生产和销售。公司的主要产品是化学药、生物药、维生素及健康消费品、农兽药。","listedPrice":4},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华北制药(600812)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华北制药(600812)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华北制药,600812,华北制药股票,华北制药股票老虎,华北制药股票老虎国际,华北制药行情,华北制药股票行情,华北制药股价,华北制药股市,华北制药股票价格,华北制药股票交易,华北制药股票购买,华北制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华北制药(600812)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华北制药(600812)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}